Kasiewicz, Lisa N.
Biswas, Souvik
Beach, Aaron
Ren, Huilan
Dutta, Chaitali
Mazzola, Anne Marie http://orcid.org/0000-0003-3300-0245
Rohde, Ellen
Chadwick, Alexandra
Cheng, Christopher
Garcia, Sara P. http://orcid.org/0000-0003-3312-6454
Iyer, Sowmya
Matsumoto, Yuri
Khera, Amit V.
Musunuru, Kiran
Kathiresan, Sekar http://orcid.org/0000-0002-3711-7101
Malyala, Padma
Rajeev, Kallanthottathil G. http://orcid.org/0000-0002-0104-0237
Bellinger, Andrew M. http://orcid.org/0000-0002-3235-2313
Article History
Received: 3 March 2022
Accepted: 14 March 2023
First Online: 15 May 2023
Competing interests
: A.V.K. is an employee and holds equity in Verve Therapeutics and has served as a scientific advisor to Amgen, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Foresite Labs, and Ambry. K.M. is an advisor to and holds equity in Verve Therapeutics and Variant Bio. S.K. is an employee and officer of Verve Therapeutics, holds equity in Verve Therapeutics, Maze Therapeutics and Relay Therapeutics, and serves on the Board of Directors of Verve Therapeutics, Maze Therapeutics, and Relay Therapeutics. A.M.B. is an employee of Verve Therapeutics and holds equity in Verve Therapeutics, Lyndra Therapeutics, Corner Therapeutics, and Cocoon Biotech. All other authors are employees of and hold equity in Verve Therapeutics. Verve Therapeutics has filed for patent protection related to various aspects of therapeutic base editing of ANGPTL3 and GalNAc-Lipid nanoparticle manufacture and delivery, including the patent publication WO2021178725.